You are here

Transdermal Patch Shows Promise in Parkinson’s Disease

Higher systemic exposure with rasagiline patch versus tablets

Positive results have been reported from a recently completed bioavailability study that examined the delivery of TPU-002RA (Teikoku Pharma USA), a 7-day rasagiline patch, for patients with Parkinson’s disease (PD). The study was part of the FDA’s recommended program for a new drug application (NDA) for TPU-002RA and will be a critical component of the product’s NDA.

TPU-002RA is a transdermal patch system that contains the same active drug component in Azilect (Teva Pharmaceuticals), the only currently marketed form of rasagiline. In the new study, one patch of rasagiline applied for 7 days achieved a higher systemic exposure than that of rasagiline 1-mg tablets (Azilect) administered orally once daily for 7 days. In addition, the patch produced more-consistent blood levels of rasagiline throughout the 7-day period without significant peaks, which were seen with the oral product.

PD is the second most common neurodegenerative disease after Alzheimer’s disease, affecting between 1.0 million and 1.5 million Americans. The primary symptoms of the disorder (stiffness, tremors, and slowed movements and gait) are caused by a loss of dopamine production by the neurons that are involved in controlling movement and coordination.

In addition to the need to develop a therapy to slow the progression of PD, several other important needs exist:

  • Alternative delivery systems to counter difficulty swallowing
  • New drugs to delay the onset of dementia with fewer adverse effects
  • A “cure” that repairs and/or reverses the neural damage
  • Simplification of complex medical regimens

Source: PR Newswire; December 2, 2014.

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs